Your Article Summary
ImmunoGen, Inc. Prices Public Offering of Common Stock
ImmunoGen, Inc., 06/19/09
ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced that it has priced a public offering of 5,000,000 shares of its common stock at a price of $7.00 per share. Net proceeds, after underwriting discounts and commissions and expenses, will be approximately $33 million. ImmunoGen has granted the underwriters a thirty day option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Article Search
Sponsor


See Latest Articles


